Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

http://scihub22266oqcxt.onion/ 32359035!ä!32359035 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Clin+Exp+Rheumatol 2020 ; 38 (3): 529-532 Nephropedia Template TP {{tp|p=32359035|t=2020. Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19 |pdf=|usr=}}{{32359035}} gab.com Text Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19 JO: Clin Exp Rheumatol http://www.kidney.de/pget.php?&tw=1&pmid=32359035 #FOAvip OBJECTIVES: No agent has yet been proven to be effective for the treatment of patients with severe COVID-19. METHODS: We conducted a pilot prospective open, single-arm multicentre study on off-label use of tocilizumab (TCZ) involving 63 hospitalised adult patients (56 males, age 62.6+/-12.5) with severe COVID-19. Clinical and laboratory parameters were prospectively collected at baseline, day 1, 2, 7 and 14. No moderate-to-severe adverse events attributable to TCZ were recorded. RESULTS: We observed a significant improvement in the levels of ferritin, C-reactive protein, D-dimer. The ratio of the partial pressure of oxygen (Pa02) to the fraction of inspired oxygen (Fi02) improved (mean+/-SD Pa02/Fi02 at admission: 152+/-53; at day 7: 283.73+/-115.9, at day 14: 302.2+/-126, p<0.05). The overall mortality was 11%; D-dimer level at baseline, but not IL-6 levels were predictors of mortality. TCZ administration within 6 days from admission in the hospital was associated with an increased likelihood of survival (HR 2.2 95%CI 1.3-6.7, p<0.05). CONCLUSIONS: In hospitalised adult patients with severe COVID-19, TCZ could be a safe option. An improvement in respiratory and laboratory parameters was observed. Future controlled trials in patients with severe illness are urgently needed to confirm the definite benefit with IL-6 target therapy. Twit Text FOAVip Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19 ????Clin Exp Rheumatol http://www.kidney.de/pget.php?&tw=1&pmid=32359035 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32359035 #FOAvip English Wikipedia <ref>{{Cite pmid|32359035}}</ref> Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19 #MMPMID32359035 Sciascia S; Apra F; Baffa A; Baldovino S; Boaro D; Boero R; Bonora S; Calcagno A; Cecchi I; Cinnirella G; Converso M; Cozzi M; Crosasso P; De Iaco F; Di Perri G; Eandi M; Fenoglio R; Giusti M; Imperiale D; Imperiale G; Livigni S; Manno E; Massara C; Milone V; Natale G; Navarra M; Oddone V; Osella S; Piccioni P; Radin M; Roccatello D; Rossi D Clin Exp Rheumatol 2020[May]; 38 (3): 529-532 PMID32359035show ga OBJECTIVES: No agent has yet been proven to be effective for the treatment of patients with severe COVID-19. METHODS: We conducted a pilot prospective open, single-arm multicentre study on off-label use of tocilizumab (TCZ) involving 63 hospitalised adult patients (56 males, age 62.6+/-12.5) with severe COVID-19. Clinical and laboratory parameters were prospectively collected at baseline, day 1, 2, 7 and 14. No moderate-to-severe adverse events attributable to TCZ were recorded. RESULTS: We observed a significant improvement in the levels of ferritin, C-reactive protein, D-dimer. The ratio of the partial pressure of oxygen (Pa02) to the fraction of inspired oxygen (Fi02) improved (mean+/-SD Pa02/Fi02 at admission: 152+/-53; at day 7: 283.73+/-115.9, at day 14: 302.2+/-126, p<0.05). The overall mortality was 11%; D-dimer level at baseline, but not IL-6 levels were predictors of mortality. TCZ administration within 6 days from admission in the hospital was associated with an increased likelihood of survival (HR 2.2 95%CI 1.3-6.7, p<0.05). CONCLUSIONS: In hospitalised adult patients with severe COVID-19, TCZ could be a safe option. An improvement in respiratory and laboratory parameters was observed. Future controlled trials in patients with severe illness are urgently needed to confirm the definite benefit with IL-6 target therapy. |*Betacoronavirus[MESH] |Aged[MESH] |Antibodies, Monoclonal, Humanized/*therapeutic use[MESH] |COVID-19[MESH] |Coronavirus Infections/*therapy[MESH] |Female[MESH] |Humans[MESH] |Male[MESH] |Middle Aged[MESH] |Off-Label Use[MESH] |Pandemics[MESH] |Pilot Projects[MESH] |Pneumonia, Viral/*therapy[MESH] |Prospective Studies[MESH] |Receptors, Interleukin-6/antagonists & inhibitors[MESH] |SARS-CoV-2[MESH]Pilot prospective open, single-arm multicentre study on off-label use (epmc).pdf DeepDyve Pubget Overpricing